Anaplastic thyroid cancer (ATC), a rare yet highly aggressive malignancy, continues to represent a major clinical challenge.

Mosaic gained ASTX029, an ERK1/2 inhibitor, and ASTX295, an MDM2 antagonist, in the deal, which it hopes to advance in biomarker-defined indications.

In many cancer types, the TP53 gene is often mutated or deleted, which inactivates the tumour suppression activity of the p53 protein. However, loss of p53 tumour-suppressor activity can also ...